REGENXBIO

+$0.71 (+2.58%) As of 5:37 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.

CEO
Kenneth T. Mills
Employees
372
Headquarters
Rockville, Maryland
Founded
2008

RGNX Key Statistics

Market cap
1.22B
Price-Earnings ratio
12.77
Dividend yield
—
Average volume
567.14K
High today
$28.41
Low today
$27.27
Open price
$27.57
Volume
118.85K
52 Week high
$46.46
52 Week low
$18.69

RGNX Earnings

-$1.58
$1.17
$3.92
$6.67
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 9, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure